BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
25 women students to receive internship, training, and mentorship in Life Sciences segment
The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments
Manageable safety profile and encouraging antitumor activity observed for MK-1084 in KANDLELIT-001, both as a monotherapy and in studied combinations
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
Subscribe To Our Newsletter & Stay Updated
